Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Clinical trial NCT05942573 · UNKNOWN

Trial details

NCT number: NCT05942573
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

Start date: 2022-12-24
Primary completion: 2023-10-01
Enrollment: 107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.